irinotecan has been researched along with Anaplastic Oligodendroglioma in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellanger, A; Carpentier, C; Dehais, C; Delattre, JY; Granger, B; Guillevin, R; Hoang-Xuan, K; Laigle-Donadey, F; Marie, Y; Meng, Y; Mokhtari, K; Psimaras, D; Rousseau, A; Sanson, M; Sierra del Rio, M; Taillibert, S; Vincent, LA | 1 |
| Chamberlain, MC | 2 |
| Almubarak, M; Altaha, R; Khan, M; Nagaiah, G | 1 |
| Affronti, ML; Allen, D; Badruddoja, M; Bigner, DD; Bohlin, C; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Silverman, S; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K | 1 |
| Affronti, ML; Allen, D; Bigner, DD; Bohlin, C; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Lentz, C; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Schweitzer, H; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K | 1 |
| Chamberlain, MC; Glantz, MJ | 1 |
| Burton, E; Prados, M | 1 |
| Ashley, D; Bigner, DD; Cloughsey, T; Cokgor, I; Colvin, OM; Elfring, GL; Friedman, AH; Friedman, HS; Haglund, M; Houghton, PJ; Kerby, T; Lawyer, J; Lovell, S; Malczyn, J; McLendon, RE; Miller, LL; Parry, M; Petros, WP; Provenzale, JM; Rasheed, K; Rich, J; Schaaf, LJ; Stewart, ES | 1 |
2 review(s) available for irinotecan and Anaplastic Oligodendroglioma
| Article | Year |
|---|---|
Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carmustine; Drug Implants; Female; Glioblastoma; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Oligodendroglioma | 2010 |
New chemotherapy options for the treatment of malignant gliomas.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine; Enzyme Inhibitors; Glioma; Humans; Irinotecan; Neovascularization, Pathologic; Oligodendroglioma; Protease Inhibitors; Signal Transduction; Temozolomide; Thalidomide | 1999 |
5 trial(s) available for irinotecan and Anaplastic Oligodendroglioma
| Article | Year |
|---|---|
Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Gastrointestinal Diseases; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oligodendroglioma; Polypharmacy; Prospective Studies; Salvage Therapy | 2002 |
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; Confidence Intervals; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Oligodendroglioma | 2004 |
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma | 2004 |
CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Chromosome Deletion; Chromosomes, Human, Pair 1; Dacarbazine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Survival Analysis; Temozolomide | 2008 |
Irinotecan therapy in adults with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Camptothecin; Disease Progression; Female; Glioblastoma; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma | 1999 |
3 other study(ies) available for irinotecan and Anaplastic Oligodendroglioma
| Article | Year |
|---|---|
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Cyclophosphamide; Dacarbazine; Glioblastoma; Humans; Irinotecan; Lomustine; Neoplasm Grading; Neoplasm Recurrence, Local; Oligodendroglioma; Procarbazine; Radiotherapy; Singapore; Temozolomide; Teniposide; Vincristine | 2015 |
Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Brain Neoplasms; Camptothecin; Cerebral Hemorrhage; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Genetic Testing; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Patient Compliance; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Chromosomes, Human, Pair 1; Genetic Predisposition to Disease; Genotype; Humans; Irinotecan; Mutation; Neoplasm Recurrence, Local; Oligodendroglioma; Survival Rate; Treatment Outcome | 2010 |